Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jul 8;279(2):119-25.
doi: 10.1016/j.canlet.2008.10.039. Epub 2008 Dec 17.

Stem cells in melanoma development

Affiliations
Review

Stem cells in melanoma development

Marianna Sabatino et al. Cancer Lett. .

Abstract

Cutaneous melanoma is a significant health problem worldwide. Available treatments can induce objective tumor regression in a small percent of patients, but these responses are not always associated with improved long-term survival. The resistance of melanoma to therapy and its predestined recurrence are related to the genetic heterogeneity and genomic instability of the tumor. For many years these genetic alterations were thought to be linked to the accumulation of random mutations in functionally differentiated cells which transform them into malignant cells that have lost their ability to differentiate and have acquired drug resistance. In the last few years it has been largely demonstrated that melanoma as other solid tumors contains a subpopulation of cells (CSCs) considered the source of the primary tumor mass, of new tumor nodules and responsible for drug resistance and cancer recurrence. In this review, we provide an overview of findings and advances in CSCs research that are relevant to the initiation, natural history, and the response to treatment of malignant melanoma.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Melanoma stem-like cells may appear after mutations occurred in melanocytes stem cells, or progenitor cells. They may also be the results of transformation in differentiated cells. They are responsible for tumor growth and metastasis.

Similar articles

  • Cancer stem cells and human malignant melanoma.
    Schatton T, Frank MH. Schatton T, et al. Pigment Cell Melanoma Res. 2008 Feb;21(1):39-55. doi: 10.1111/j.1755-148X.2007.00427.x. Pigment Cell Melanoma Res. 2008. PMID: 18353142 Free PMC article. Review.
  • Nevi and Melanoma.
    Zhang Y, Ostrowski SM, Fisher DE. Zhang Y, et al. Hematol Oncol Clin North Am. 2024 Oct;38(5):939-952. doi: 10.1016/j.hoc.2024.05.005. Epub 2024 Jun 15. Hematol Oncol Clin North Am. 2024. PMID: 38880666 Review.
  • Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.
    Kong Y, Kumar SM, Xu X. Kong Y, et al. Arch Pathol Lab Med. 2010 Dec;134(12):1740-9. doi: 10.5858/2009-0418-RAR.1. Arch Pathol Lab Med. 2010. PMID: 21128770 Free PMC article. Review.
  • MITF pathway mutations in melanoma.
    Yokoyama S, Salma N, Fisher DE. Yokoyama S, et al. Pigment Cell Melanoma Res. 2009 Aug;22(4):376-7. doi: 10.1111/j.1755-148X.2009.00599.x. Epub 2009 Jun 25. Pigment Cell Melanoma Res. 2009. PMID: 19558635 No abstract available.
  • Molecular pathogenesis of cutaneous melanocytic neoplasms.
    Ibrahim N, Haluska FG. Ibrahim N, et al. Annu Rev Pathol. 2009;4:551-79. doi: 10.1146/annurev.pathol.3.121806.151541. Annu Rev Pathol. 2009. PMID: 19400696 Review.

Cited by

References

    1. Beddingfield FC., III The melanoma epidemic: res ipsa loquitur. Oncologist. 2003;8:459–465. - PubMed
    1. Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Orlow I, Panageas K, Chapman PB. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol. 2008;26:2299–2304. - PubMed
    1. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–2357. - PMC - PubMed
    1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111. - PubMed
    1. Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz DB, Lewis DW, Gollin SM, Gamblin TC, Geller DA, Lagasse E. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res. 2008;68:6932–6941. - PMC - PubMed